Bayer/J&J plan a complete response to the FDA on anticoagulant Xarelto
This article was originally published in Scrip
Executive Summary
Bayer and Johnson & Johnson plan to submit a reply to the US FDA's complete response letter on Xarelto (rivaroxaban), a potential blockbuster anticoagulant, in the fourth quarter of this year.